173774-48-6

Basic information

• Product Name: (R)-1-N-BOC-4-N-BOC-PIPERAZINE-2-CARBOXYLIC ACID
• Synonyms: (R)-1-N-BOC-4-N-BOC-PIPERAZINE-2-CARBOXYLIC ACID;1,2,4-Piperazinetricarboxylic acid, 1,4-bis(1,1-diMethylethyl) ester, (2R)-
• CAS NO: 173774-48-6
• Molecular Formula: C₁₅H₂₆N₂O₆
• Molecular Weight: 330.378
• Mol File: 173774-48-6.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 443.888 °C at 760 mmHg
• Flash Point: 222.256 °C
• Appearance: /
• Density: 1.201 g/cm³
• Refractive Index: 1.503
• Storage Temp.: 2-8°C
• PKA: 3.70±0.20(Predicted)
• CAS DataBase Reference: (R)-1-N-BOC-4-N-BOC-PIPERAZINE-2-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-1-N-BOC-4-N-BOC-PIPERAZINE-2-CARBOXYLIC ACID(173774-48-6)
• EPA Substance Registry System: (R)-1-N-BOC-4-N-BOC-PIPERAZINE-2-CARBOXYLIC ACID(173774-48-6)

Safety Data

• Hazardous Substances Data: 173774-48-6(Hazardous Substances Data)

Usage

Description

(R)-1-N-BOC-4-N-BOC-PIPERAZINE-2-CARBOXYLIC ACID is a chemical compound that belongs to the class of piperazine carboxylic acids. It is a derivative of piperazine and is widely recognized for its role as a building block in the synthesis of various pharmaceutical compounds. (R)-1-N-BOC-4-N-BOC-PIPERAZINE-2-CARBOXYLIC ACID is characterized by the presence of BOC (tert-butoxycarbonyl) protecting groups on both nitrogen atoms, which are crucial for controlling the reactivity of the compound during chemical reactions. As a key intermediate, (R)-1-N-BOC-4-N-BOC-PIPERAZINE-2-CARBOXYLIC ACID is instrumental in the development of drugs for treating a range of disorders and diseases, making it an essential component in the pharmaceutical industry.

Uses

Used in Pharmaceutical Industry:
(R)-1-N-BOC-4-N-BOC-PIPERAZINE-2-CARBOXYLIC ACID is used as a key intermediate in the synthesis of various pharmaceutical compounds for the treatment of different disorders and diseases. Its presence of BOC protecting groups on nitrogen atoms allows for controlled reactivity during chemical reactions, facilitating the development of therapeutic agents with desired properties.
Used in Drug Synthesis:
(R)-1-N-BOC-4-N-BOC-PIPERAZINE-2-CARBOXYLIC ACID is utilized as a building block in the synthesis of drugs, contributing to the creation of novel therapeutic agents with improved efficacy and safety profiles. The BOC protecting groups on the nitrogen atoms enable selective reactions and functional group manipulations, allowing for the synthesis of complex drug molecules with specific pharmacological properties.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, (R)-1-N-BOC-4-N-BOC-PIPERAZINE-2-CARBOXYLIC ACID serves as a valuable compound for the exploration of new drug candidates. Its unique structure and reactivity make it an attractive starting material for the design and synthesis of potential therapeutic agents, enabling researchers to investigate its potential in treating various medical conditions.
Overall, (R)-1-N-BOC-4-N-BOC-PIPERAZINE-2-CARBOXYLIC ACID is a versatile and essential compound in the pharmaceutical industry, playing a crucial role in the development of new drugs and therapeutic agents for the treatment of various disorders and diseases. Its unique properties and reactivity make it a valuable asset in drug synthesis, medicinal chemistry research, and the advancement of pharmaceutical science.

InChI:InChI=1/C15H26N2O6/c1-14(2,3)22-12(20)16-7-8-17(10(9-16)11(18)19)13(21)23-15(4,5)6/h10H,7-9H2,1-6H3,(H,18,19)/t10-/m1/s1

Upstream product

• 192330-11-3 (R)-4-(tert-butoxycarbonyl)piperazine-2-carboxylic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 3022-15-9 piperazine-2-carboxylic acid dihydrochloride 
• 31321-68-3 (R)-piperazine-2-carboxylic acid 
• 637027-24-8 (R)-piperazine-1,2,4-tricarboxylic acid 1,4-di-tert-butyl ester 2-methyl ester 

Downstream Products

• 1159598-21-6 (R)-2-hydroxymethylpiperazine-1,4-dicarboxylic acid di-tert-butyl ester 
• 1589081-62-8 (R)-2-benzoylpiperazine-1,4-dicarboxylic acid di-tert-butyl ester 
• 1589081-63-9 (R)-2-(hydroxyphenylmethyl)piperazine-1,4-dicarboxylic acid di-tert-butyl ester 
• 1589081-64-0 (R)-2-(fluorophenylmethyl)piperazine-1,4-dicarboxylic acid di-tert-butyl ester 
• 1589081-66-2 (R)-2-(4-fluorobenzoyl)piperazine-1,4-dicarboxylic acid di-tert-butyl ester 
• 1589081-67-3 (R)-2-[(4-fluorophenyl)hydroxymethyl]piperazine-1,4-dicarboxylic acid di-tert-butyl ester 
• 1586810-40-3 (R)-2-(methoxymethylcarbamoyl)piperazine-1,4-dicarboxylic acid di-tert-butyl ester 
• 438631-77-7 (3R)-1,3-piperazinedicarboxylic acid, 1-(1,1-dimethylethyl) 3-methyl ester 
• 1399848-04-4 di-tert-butyl (2R)-2-{[{(1S)-1-[1-(3-methoxypropyl)-3,4-dimethyl-1H-indazol-6-yl]ethyl}(cyclopropyl)amino]carbonyl}piperazine-1,4-dicarboxylate 
• 1399848-03-3 di-tert-butyl (2R)-2-{[{(1R)-1-[1-(3-methoxypropyl)-3,4-dimethyl-1H-indazol-6-yl]ethyl}(cyclopropyl)amino]carbonyl}piperazine-1,4-dicarboxylate 
• 1399848-02-2 di-tert-butyl (2R)-2-{[{(1S)-1-[3-chloro-1-(3-methoxypropyl)-1H-indol-6-yl]ethyl}(cyclopropyl)amino]carbonyl}piperazin-1,4-dicarboxylate 
• 1399848-01-1 di-tert-butyl (2R)-2-{[{(1R)-1-[3-chloro-1-(3-methoxypropyl)-1H-indol-6-yl]ethyl}(cyclopropyl)amino]carbonyl}piperazin-1,4-dicarboxylate 
• 1361223-70-2 2-(4-((2S)-4-((5-nitro-2-thiophenyl)sulfonyl)-2-(((3S)-3-methyl-4-morpholinyl)methyl)-1-piperazinyl)phenyl)-1,1,1,3,3,3-hexafluoro-2-propanol 
• 1361223-67-7 2-(4-((2S)-4-((5-amino-2-thiophenyl)sulfonyl)-2-(((3S)-3-methyl-4-morpholinyl)methyl)-1-piperazinyl)phenyl)-1,1,1,3,3,3-hexafluoro-2-propanol 

Relevant articles and documents

Bis(vinylsulfonyl)piperazines as efficient linkers for highly homogeneous antibody-drug conjugates

Disulfide re-bridging strategy has demonstrated significant advantages in the construction of homogeneous antibody drug conjugates (ADCs). However, a major issue that disulfide scrambling at the hinge region of antibody leads to the formation of “half-antibody” has appeared for many re-bridging linkers. We present bis(vinylsulfonyl)piperazines (BVP) as efficient linkers to selectively re-bridge disulfides at the antigen-binding fragment (Fab) regions and produce highly homogeneous conjugates with a loading of two drugs without disulfide scrambling. We also found that optically active (S)-configuration linkers led to more sufficient conjugation compared with (R)-configuration. The BVP-linked ADCs demonstrated superior efficacy and antigen-selectivity in vitro cytotoxicity.

HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ABNORMAL CELLULAR PROLIFERATION

This invention is in the area of heterocyclic-based compounds for the treatment of disorders involving abnormal cellular proliferation, including but not limited to tumors and cancers.

Human Adam-10 Inhibitors

Magnesium salts/complexes of compounds useful for inhibiting the ADAM-IO protein and methods of making and purifying them are provided. Further provided are compositions comprising magnesium salts/complexes of the compounds in combination with a pharmaceutically acceptable carrier. The compounds well as such compositions comprising them are useful for the treatment of cancer, arthritis, diseases related to angiogenesis, such as renal diseases, heart diseases, such as heart failure, atherosclerosis, and stroke, inflammation, ulcer, infertility, scleroderma, endometriosis, mesothelioma, and diabetes. In addition, methods of treating forms of cancer, arthritis, and diseases related to angiogenesis in which ADAM-10 plays a critical role are provided.